This clinical trial aims to evaluate the effectiveness and safety of a new medication for asthma patients. Participants will be randomly assigned to receive either the new medication or a placebo. The study will monitor the participants' asthma symptoms and overall health over a period of 12 weeks.
- Who Can Participate: Individuals aged 18-65 with a diagnosis of asthma for at least one year
- Study Details: Participants will receive either the new asthma medication or a placebo and will be required to attend regular check-ups over a 12-week period
- Study Timelines and Visits: The study will begin in January 2024 and conclude in April 2024.Participants will need to attend 5 visits over the course of the study